we are leaders in counselling and psychotherapy
从12月1日起，Ibrutinib,也称为Imbruvica将被列入药物补贴计划（ PBS ），病人每个处方仅需38.80澳元就可获得，如果持有折扣卡，则只需6.30澳元。
A breakthrough leukaemia and lymphoma drug that normally costs $187,000 per treatment will become easily affordable under a new $460 million Turnbull government subsidy.
Ibrutinib, known as Imbruvica, will cost patients $38.80 a script – or $6.30 for concessional patients - once it is listed on the Pharmaceutical Benefits Scheme from December 1.
The drug will be available to all eligible patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Prime Minister Malcolm Turnbull will announce the listing on Monday, saying the drug – considered significantly more effective than many of the treatments already available through the PBS – will change lives.
"This new medicine provides an important new treatment option for Australian patients and now, thanks to my government's commitment to the PBS, is within reach for hundreds of Australian families," Mr Turnbull said.
Around 1000 Australians are expected to benefit from the drug every year.
link to The AGE
Melbourne Agape Psychocare
1 Queens Road, Melbourne 3004
中国驻澳大利亚大使馆 澳大利亚移民局 维省公共交通查询 澳洲华人专业人士俱乐部 澳大利亚留学生冤情大使 Medibank Private Australian Unity E-Health Doctor's Health Fund Bupa NDIS
Copyright © 2011-2018 Melbourne Agape Psychocare 警告：此外网页内容版权为墨尔本博爱心理咨询及治疗专科所有，禁止任何的抄袭和盗取内容。 ABN 76 733 009 963